The company is also planning to file an investigational new drug application with the United States Food and Drug Administration before the year ends in the hopes of advancing PRT2070, which has already been pre-clinically tested for treatment and prevention of ophthalmological diseases.
Currently, Portola Pharmaceuticals Inc (NASDAQ:PTLA) has 28 issued U.S. patents, 43 U.S. patent applications and 93 issued patents and 170 patent applications in other jurisdictions. They are also the co-owner of 12 additional patents and patent applications. By the end of April, Portola had licensed 156 issued patents and 78 patent applications from third parties, mostly on an exclusive basis.
With a large IP portfolio, a late-stage product, and a large patient population, Portola Pharmaceuticals Inc (NASDAQ:PTLA)presents large upside potential. Betrixaban alone has peak sales potential of $500 million, with the potential for expanded indications. Thus, with two years until data and enough cash to avoid dilution, Portola Pharmaceuticals Inc (NASDAQ:PTLA) looks to be a safe, under-the-radar investment that could produce very large gains pending a successful Phase III study.
So there are many reasons why these two stocks are performing so well, the number one reason is probably that the human race has great hope and high expectations. Looking at both companies at a distance, one can see that both bio-pharmaceutical companies have strong support through in-depth collaboration and investment density.
Both companies are in fact providing hope for many patients across the globe through the introduction of breakthrough drugs that would offer a cure to a widespread problem. Both companies have preservation, they know what the public needs, and refuse to give up. I believe these pharmaceutical companies will revolutionize today’s diagnoses and treatments of diseases the way Apple revolutionized digital music with its iPods and its computing devices with iPad.
In other words, these are two recent IPOs, and bio pharmaceutical companies, that I like very much in the years ahead.
The article Why Are These 2 Recent IPOs So Promising To You? originally appeared on Fool.com and is written by Sherrie Stone.
Sherrie Stone has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Sherrie is a member of The Motley Fool Blog Network — entries represent the personal opinion of the blogger and are not formally edited.
Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.